Get the Stockscreener App
54.89
2.80%
1.4932
Vaxcyte Inc stock is traded at $54.89, with a volume of 349.66K.
It is up +2.80% in the last 24 hours and up +16.87% over the past month.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
See More
Previous Close:
$53.40
Open:
$53.22
24h Volume:
349.66K
Relative Volume:
0.27
Market Cap:
$7.19B
Revenue:
-
Net Income/Loss:
$-507.65M
P/E Ratio:
-11.93
EPS:
-4.6
Net Cash Flow:
$-616.24M
1W Performance:
+15.52%
1M Performance:
+16.87%
6M Performance:
+49.86%
1Y Performance:
-39.62%
1-Day Range:
$52.84
$55.11
1-Week Range:
$46.91
$56.04
52-Week Range:
$27.66
$93.77
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
54.93 | 6.99B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.44 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.51 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.92 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
358.61 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.92 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Reiterated | Needham | Buy |
| Sep-12-25 | Initiated | Goldman | Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-24 | Initiated | Goldman | Buy |
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
Vaxcyte, Inc. (PCVX) Stock Analysis: Strong Analyst Consensus and Nearly 94% Upside Potential - directorstalkinterviews.com
Evercore ISI Rates Vaxcyte Inc. (PCVX) as an Overweight Following CDC Changes to Childhood Vaccination Recommendations - Finviz
Analysts Are Bullish on These Healthcare Stocks: Vaxcyte (PCVX), Guardant Health (GH) - The Globe and Mail
Vaxcyte updates on programs for VAX-31 - The Pharma Letter
Trading the Move, Not the Narrative: (PCVX) Edition - Stock Traders Daily
Vaxcyte (PCVX) Is Up 13.2% After Expanding Late-Stage VAX-31 Program And Manufacturing Plans - Yahoo Finance
Cantor Fitzgerald reiterates Overweight rating on Vaxcyte stock By Investing.com - Investing.com Canada
Guggenheim Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $116 - 富途牛牛
Stocks to watch: Vaxcyte sees RS rating jump to 83 - MSN
Vaxcyte Pushes Next-Gen Pneumococcal Vaccine Into Phase 3 Phase - Benzinga
Vaxcyte (PCVX) Advances VAX-31 Vaccine Trials - GuruFocus
Vaxcyte advances adult and infant programs for Vax-31, a potential best-in-class, next-generation pneumococcal conjugate vaccine - marketscreener.com
Vaxcyte Advances Adult and Infant Programs for VAX-31, a - GlobeNewswire
Vaxcyte stock up on results from mid-stage trial of its pneumococcal vaccine - MSN
Campbell & CO Investment Adviser LLC Cuts Stake in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Vaxcyte (NASDAQ:PCVX) Trading 7.4% HigherWhat's Next? - MarketBeat
Aug Update: Can Vaxcyte Inc stock hit record highs againCPI Data & Technical Entry and Exit Alerts - Bộ Nội Vụ
(PCVX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Aug Patterns: Why Vaxcyte Inc. (5VA) stock remains stableTrade Analysis Summary & Proven Capital Preservation Methods - Bộ Nội Vụ
Vaxcyte, Inc. (PCVX) Stock Analysis: A Look At Its 121.74% Potential Upside - DirectorsTalk Interviews
Analyst Calls: Will Vaxcyte Inc. (5VA) stock test record highs in 2025Weekly Stock Analysis & Real-Time Market Sentiment Reports - Bộ Nội Vụ
CEO Change: Why Vaxcyte Inc stock could benefit from AI revolutionQuarterly Trade Summary & Expert Approved Momentum Ideas - moha.gov.vn
How Vaxcyte Inc. stock performs after earningsRecovery Day Options & choose cushioning that matches your runs - Улправда
Why Vaxcyte Inc. (5VA) stock could rally stronglyLong Run Comfort Guide & updated model highlights and notes - Улправда
Cantor Fitzgerald Maintains Overweight on Vaxcyte Amid Vaccine Development and ACIP Meeting - MSN
How Vaxcyte Inc. (5VA) stock responds to bond market2025 Key Lessons & High Conviction Trade Alerts - Улправда
Why Vaxcyte Inc. stock could benefit from AI revolutionJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - Улправда
Why Vaxcyte Inc. stock attracts high net worth investorsJuly 2025 Weekly Recap & Expert Verified Stock Movement Alerts - Улправда
Is Vaxcyte Inc. (5VA) stock positioned for digital growth eraJuly 2025 Macro Moves & Free Community Consensus Stock Picks - Улправда
Will Vaxcyte Inc. (5VA) stock test record highs in 20252025 Trade Ideas & Long-Term Growth Plans - Улправда
Why Vaxcyte Inc. (5VA) stock remains stableMoving Average Strategies & Secret Picks Wall Street Isn’t Talking About - ulpravda.ru
Vaxcyte (PCVX) Gains Positive Outlook with Price Target Boost - GuruFocus
Evercore ISI reiterates Outperform rating on Vaxcyte stock amid CDC changes - Investing.com Canada
Stock Report: Is Vaxcyte Inc stock trading near support levelsSell Signal & Daily Profit Maximizing Trade Tips - moha.gov.vn
Vaxcyte (PCVX) Gains Favor After Immunization Schedule Update - GuruFocus
Vaxcyte, Inc. (PCVX) Stock Analysis: Biotech Innovator With Nearly 100% Upside Potential - DirectorsTalk Interviews
Vaxcyte's Chief Technical Ops Officer Sells Shares - AOL.com
Insider Sell Alert: Harpreet Dhaliwal Sells 9,743 Shares of Vaxc - GuruFocus
Harpreet Dhaliwal Sells 9,743 Shares of Vaxcyte (NASDAQ:PCVX) Stock - MarketBeat
Vaxcyte Inc. (PCVX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Price-Driven Insight from (PCVX) for Rule-Based Strategy - Stock Traders Daily
Vaxcyte, Inc. (NASDAQ:PCVX) Nasdaq Composite Tracks Clinical Progress - Kalkine Media
Vaxcyte shows rising price performance with jump to 81 RS rating - MSN
Trade Alert: Senior Vice President of Finance Of Vaxcyte Elvia Cowan Has Sold Stock - simplywall.st
Vaxcyte (NASDAQ:PCVX) Stock Price Up 3.9%Here's Why - MarketBeat
Vaxcyte Earnings Notes - Trefis
Insider Selling: Vaxcyte (NASDAQ:PCVX) SVP Sells 11,623 Shares of Stock - MarketBeat
Vaxcyte president and CFO sells shares worth $692,100 - MSN
Vaxcyte, Inc. $PCVX Shares Sold by Harbor Capital Advisors Inc. - MarketBeat
This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%. - Barron's
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):